|Year : 2011 | Volume
| Issue : 5 | Page : 536-540
Evaluation of Cynanchum otophyllum glucan sulfate against human immunodeficiency virus and herpes simplex virus as a microbicide agent
Jian Tao1, Jing Yang2, Chaoyin Chen3, Xiaomei Cao4, Shenglan Zhao5, Kunlong Ben4
1 Department of Pharmacology, Kunming University, Yunnan; Laboratory of Cell and Molecular Immunology, Kunming Institute of Zoology, Chinese Academy of Sciences, Yunnan, China
2 Laboratory of Cell and Molecular Immunology, Kunming Institute of Zoology, Chinese Academy of Sciences, Yunnan; Department of Chemical Processing of Forest Products, Southwest Forestry University, Yunnan, China
3 Department of Life Science and Technology, Kunming University of Science and Technology, Yunnan, China
4 Laboratory of Cell and Molecular Immunology, Kunming Institute of Zoology, Chinese Academy of Sciences, Yunnan, China
5 Department of Chinese Materia Medica, Yunnan University of Traditional Chinese Medicine, Kunming, Yunnan, China
|Date of Submission||18-Aug-2010|
|Date of Decision||26-Oct-2010|
|Date of Acceptance||01-Jul-2011|
|Date of Web Publication||15-Sep-2011|
Laboratory of Cell and Molecular Immunology, Kunming Institute of Zoology, Chinese Academy of Sciences, Yunnan
Source of Support: None, Conflict of Interest: None
Objective : The root ofCynanchum otophyllum -also known as Qing Yang Sheng-is a traditional ethnical Chinese medicine. The objective of this study was to evaluate in vitro activities and safety of C. otophyllum glucan sulfate (PS20) against Human Immunodeficiency Virus (HIV) and Herpes Simplex Virus (HSV). Materials and Methods : Anti-HIV activity was detected with syncytial formation assay and quantitative P24 Enzyme-Linked Immunosorbent Assay (ELISA). Anti-HSV activity was detected with plaque reduction assay; cytotoxicity was tested with MTT colorimetric assay; and anti-bacterial activity was tested with microdilution method. Anti-HIV mechanism was investigated with fusion inhibition, time of addition, and pretreatment. Results : The 50% Inhibition Concentration (IC 50 ) of PS20 for HIV-1 IIIB , HIV- Ada-M , HIV-1 Bal , HSV-I, and -II were 0.26 ± 0.02 mM, 0.46 ± 0.02 mM, 0.90 ± 0.04 mM, 3.45 ± 0.85 mM, and 0.70 ± 0.22 mM, respectively. Selectivity Indices (SI) were 653, 50, 39, 85, and 362, respectively. Studies on anti-HIV mechanism of PS20 showed that the target molecule should be the envelope protein. The 50% Cytotoxicity Concentrations (CC 50 ) of PS20 for HeLa and ME-180 cell lines and human foreskin fibroblast cells was more than 70 mM. The Minimum Inhibitory Concentration (MIC) for vaginal lactobacilli was more than 1000 mM. Conclusion : PS20 possesses anti-HIV and HSV effect and low cytotoxicity to epithelium cells and vaginal lactobacilli. It may be considered as a potential microbicide agent for further investigation.
Keywords: Cynanchum otophyllum , Human Immunodeficiency Virus, Herpes Simplex Virus, microbicide
|How to cite this article:|
Tao J, Yang J, Chen C, Cao X, Zhao S, Ben K. Evaluation of Cynanchum otophyllum glucan sulfate against human immunodeficiency virus and herpes simplex virus as a microbicide agent. Indian J Pharmacol 2011;43:536-40
|How to cite this URL:|
Tao J, Yang J, Chen C, Cao X, Zhao S, Ben K. Evaluation of Cynanchum otophyllum glucan sulfate against human immunodeficiency virus and herpes simplex virus as a microbicide agent. Indian J Pharmacol [serial online] 2011 [cited 2021 Nov 28];43:536-40. Available from: https://www.ijp-online.com/text.asp?2011/43/5/536/84967
| » Introduction|| |
Globally more than 85% of new Human Immunodeficiency Virus (HIV) infections spread through unprotected intercourse. The comprehensive approaches to reduce HIV infection have been intensively promoted. Male and female condoms are the powerful prophylaxis methods for preventing sexual transmission of HIV. However, their usage depends on the consent of male sexual partner, and is not always a feasible option for most women. Development of a new prevention method that women can control is urgently needed. Microbicides that can be applied inside the vagina and rectum to protect against HIV has been recognized as an attractive method similar to the anti-HIV vaccine for preventing HIV-1 transmission.  Natural products are an important resource of leading compounds in development of anti-HIV drugs. , Most polysaccharides derived from numerous species have been found to exert a potent in vitro inhibitory effect against HIV-1. 
The roots of Cynanchum otophyllum, belonging to family Asclepiadaceae and named Qing Yang Sheng, is a traditional ethnical Chinese medicine used for treating viral infections (viral hepatitis, herpes, and influenza), epilepsy, and rheumatism in South-West China. C. otophyllum glucan sulfate (PS20) has been reported to possess anti-HIV and anti-Herpes Simplex Virus (anti-HSV) activities. , In this study, we report in vitro anti-HIV and HSV activities and safety of PS20 as a microbicide agent.
| » Materials and Methods|| |
Cell Lines, Viruses, Chemicals, and Reagents
The human T-lymphocytic cell lines C8166, H9 and H9/HIV-1 IIIB were obtained from the Centralized Facility for AIDS Reagents, National Institute for Biological Standards and Control (NIBSC), UK. The human epithelial carcinoma cell lines ME-180 and HeLa cells were from American Type Culture Collection (ATCC) (Rockville, MD). The primary human foreskin fibroblast cells were prepared as described previously.  HIV-1 IIIB (CXCR4-tropic, X4), HIV-1 Ada-M , and HIV-1 Bal (CCR5-tropic, R5) were obtained from the Centralized Facility for AIDS Reagents, NIBSC, UK. All chemicals and reagents except those indicated below were purchased from Sigma (St Louis, MO).
The rhizome of C. otophyllum was bought from Lijiang Pharmaceutical Co, Yunnan Baiyao Group, Yunnan, China. It was identified by Professor Rong-hua Zhao and a voucher specimen (YUTCM, No. 0306151) was deposited in the Herbarium of Yunnan University of Traditional Chinese Medicine, Kunming, China.
Preparations of Extracts
The dried powder of the rhizome of C. otophyllum was extracted with Χ10 boiling purified H 2 O for 1 h, and the aqueous extract was centrifuged at Χ2,000 g for 15 min. The supernatant was evaporated. The crude polysaccharide was then extracted by selective ethanol precipitation, ie, discarding the material precipitated at 50% (v/v) ethanol and harvesting the material precipitated at 70% (v/v) ethanol. The product was further deproteinized using a Sevage reagent [CHCl 3 :1-butanol = 4:1(v:v)], and applied to Sephadex G75 column and thereafter to an anion exchange DEAE-Sephadex A 50 column for further purification. The purified polysaccharide was finally lyophilized. The polysaccharide content of the purified product was 94% and detected by phenol-sulfuric acid method. For generating polysaccharide sulfate (PS20), 1 g of the lyophilized polysaccharide was suspended in 10 ml anhydrous pyridine at room temperature, and mixed with 15 ml of pyridine-chlorosulfonic acid complex. After 2 h of reaction at 65°C, the PS20 solution was brought to room temperature, and the pH was adjusted to 6.5-7.0 with 2.0 M NaOH. The PS20 solution was isolated from salts by dialysis, and lyophilized. The total polysaccharide content of PS20 was 62.3%, detected by phenol-sulfuric acid method; and SO 3 Na content was 34.2%, measured by indirect spectrophotometry. The chemical structure of PS20 was defined as P-D-(1-4)-glucan sulfate by Professor Mu [Figure 1]a. 
|Figure 1: Chemical structure and anti-HIV-1IIIB mechanism of PS20 (Cynanchum otophyllum glucan sulfate). (a) Chemical structure of Cynanchum otophyllum beta-D-(1-4)-glucan sulfate. (b) Time-of-addition experiment. (c) Inhibition of cell-cell fusion. C8166 cells and H9/HIV-1IIIB cells were co-cultured for 1 day in the presence of serially diluted PS20 or AZT. (d) Dose-response curves of PS20 anti-HIV-1IIIB activity in different pretreatments|
Click here to view
Measurement of Anti-HIV Activity Analysis of Syncytial Formation
Anti-HIV-1 IIIB activity was detected as described previously. , Briefly, serially diluted compounds in RPMI 1640 medium were added to a 96-well plate in triplicate, and then 3 Χ 10 4 C8166 cells and 200 50% Cell Culture Infectious Dose (CCID 50 ) of HIV-l IIIB were added to each well. After incubation at 37°C for 72 h, syncytial cells from five different fields of each well were scored under an inverted microscope (Χ100). The percent inhibition of syncytial formation was calculated by percentage of syncytial number in compound treated culture to that in viral infected control culture.
Anti-HIV-l Ada-M and HIV-l Bal activities were analyzed by measuring supernatant p24 antigen according to the manufacturer's protocol (Perkin-Elmer). Briefly, Peripheral Blood Mononuclear Cells (PBMC) from normal donor were isolated by Ficoll-Hypaque gradient centrifugation, and cultured in the presence of 5 mg/ml Phytohemagglutinin (PHA) and Interleukin-2 (IL-2) (20 U/ml) (Sigma, USA) for 72 h. The non-adherent PBMCs were then removed, and remaining adherent cells were infected with HIV-1 Ada-M or HIV-1 Bal in the presence and absence of serially diluted PS20. After 7-14 days of culture in IL-2- and PHA-containing complete medium, the virus replicates in supernatant of each well were detected with p24 antigen ELISA. The percent inhibition of p24 antigen production was calculated by percentage of p24 level in PS20-treated culture to that in viral-infected culture without PS20.
Time-of-addition experiment was carried out as described previously by Tao et al. In brief, C8166 cells were preincubated with HIV-1 IIIB [Multiplicity Of Infection (MOI) = 1.0] for 1 h at 4°C to allow HIV-1 to attach to cells without fusion, and subsequently washed three times with ice-cold medium to remove unbound viruses. Cells were then rapidly warmed to 37°C to allow the viral replication cycle to proceed. Compounds at a concentration of 100-fold IC 50 were added at different time points (0, 10, 30, 45, 60, 120, 240, 360, 480, and 600 min post infection). Viral p24 antigen production was determined 72 h post infection using P24 ELISA assay.
Cell Fusion Assay
Cell fusion assay was performed as described previously. , In the assay, 3 Χ 10 4 C8166 cells and 1 Χ 10 4 H9/HIV-1 IIIB cells per well were mixed and co-cultured in a 96-well plate in the presence or absence of serially diluted compounds PS20 or Azidothymidine (AZT) for 24 h. The number of syncytial cells in each well was counted under a microscope.
Pretreatment experiments were carried out as previously described. , In the treatment 1, 3 Χ 10 4 C8166 cells, 200 CCID 50 of HIV-1 IIIB and serially diluted PS20 were co-cultured in a 96-well plate at 37°C for 1.5 h, washed three times with RPMI 1640 medium at Χ400 g centrifugation, and cultured for another 72 h before syncytia were counted under a microscope. In treatment 2, HIV-1 IIIB was pretreated with serially diluted PS20 at 37°C for 1.5 h, washed three times and filtered with Microcon YM-100 (Millipore). PS20-pretreated HIV-1 IIIB and 3 Χ 10 4 C8166 cells per well in a 96-well plate were co-cultured for 1.5 h, washed three times, and cultured for another 72 h before syncytia were counted. In treatment 3, C8166 cells were pretreated with serially diluted PS20 at 37°C for 3 h, and washed three times. About 200 CCID 50 of HIV-1 IIIB and 3 Χ 10 4 PS20-pretreated C8166 cells per well in a 96-well plate were co-cultured at 37°C for 1.5 h, washed three times, and cultured for another 72 h before syncytia were counted.
Anti-HSV activity was detected by plaque reduction assay as described previously. ,, Briefly, Vero cells were incubated at 37°C for 24 h in a 24-well plate. Confluent Vero cell monolayers were infected with 200 CCID 50 of HSV-I or HSV-II in the presence or absence of serially diluted compounds. After adsorption at 37°C for 1 h, the inoculum was aspirated and washed with 1 ml Phosphate Buffered Saline (PBS). Unsolid 1 ml of 0.4% agar in RPMI 1640 complete medium was added. The cultures was incubated for 3 days until plaques appeared, fixed with 2% formalin, and stained with 0.4% crystal violet for 20 min. The plaques were counted under a microscope after removal of the agar overlay. The IC 50 was calculated as the compound concentration required reducing virus plaques by 50%.
Measurement of Cytotoxicity
Compound cytotoxicity to cervical epithelial cells, C8166 cells, PBMC, and primary cultured foreskin fibroblast cells was determined by 3,(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay as described previously.  Briefly, cells were cultured at 37°C for 44 h in the presence or absence of serially diluted compounds in triplicate. MTT stock solution was added to each well. After 4 h of incubation, cell lysis buffer (20% sodium dodecyl sulfate-N0,N-dimethyl formamide (SDS-DMF) were pipetted into each well. After 4 h of incubation, the plates were read on a microplate ELISA reader.
Toxicity Analysis to Human Vaginal Lactobacilli
Lactobacillus delbrueckii was isolated from the vagina of a healthy woman and grown in Lactobacilli MRS broth.  To assess the toxicity of the compound to L. delbrueckii growth, a microdilution assay was used. Briefly, lactobacilli were added into a 96-well plate at 10 6 colony-forming units (CFU)/ml per well in the presence of the serially diluted compound. The Minimum Inhibitory Concentration (MIC) of a compound was defined as the highest concentration of a compound in the well with clear culture. After cultured for 24 h at 37°C in an anaerobic Gas Pakpouch (BioMerieux, Marcy, France), the MIC was determined.
Statistical calculations and curve fitting were performed using GraphPad Prism (GraphPad Software, Inc, San Diego, CA). Data are expressed as mean ± standard deviation (SD) of three independent experiments.
| » Results|| |
PS20 has Strong Anti-HIV-1 Activity
To determine the anti-HIV-1 activity of PS20, a panel of HIV-1 strains, including R5 HIV-1 Ba-L , R5 HIV-1 Ada-M , and X4 HIV-1 IIIB , was used in this study, and its IC 50 s are 0.90 ± 0.04 mM, 0.46 ± 0.02 mM, and 0.26 ± 0.02 mM, respectively [Table 1]. These results showed that PS20 potently inhibited the infection of R5 and X4 viruses.
PS20 Demonstrates Anti-HSV Activity
As sexually transmitted HSV may enhance the likelihood of acquiring and/or transmitting HIV infection, plaque reduction assay was applied to test whether PS20 can also suppress the replication of HSV. As shown in [Table 2], our data indicated that PS20 can indeed inhibit both HSV-I and HSV-II replication; moreover, its IC 50 against HSV-I and HSV-II was 3.45 + 0.85 mM and 0.70 + 0.22 mM, respectively.
PS20 Inhibits HIV-1 Infection by Targeting Viral Entry
Few experiments were carried out to elucidate the anti-HIV mechanism of PS20. As shown in the time-of-addition experiments [Figure 1]b, PS20 almost completely inhibited HIV-1 replication when added between 0 and 60 min post-HIV infection, and its anti-HIV-1 activity dramatically decreased when added at later time points. As a control, AZT, a reverse transcriptase inhibitor, showed anti-HIV-1 activity when added as late as at 8 h post infection [Figure 1]b. These data suggest that PS20 inhibits HIV-1 infection by targeting viral early lifecycle before reverse transcription.
The interaction between HIV-1 envelope glycoprotein and host cell receptor and co-receptor may induce syncytium formation or cell-cell fusion. A cell fusion assay was used to determine whether the inhibition of syncytium formation by PS20 was due to blockade of interaction between envelope glycoprotein and cellular receptor and co-receptor. As seen in [Figure 1]c, inhibition of syncytium formation by PS20 was dose-dependent, while a control compound AZT did not show any activity of inhibiting syncytium formation in cell-cell fusion, indicating that PS20 prevented the syncytium formation/cell fusion likely through blocking the interaction between envelope glycoprotein and cell receptor and co-receptor. In addition, to further understand whether PS20 interacts with viral envelope glycoprotein and/or cellular receptor or co-receptor, PS20 pretreatment experiments were subsequently performed [Figure 1]d. The pretreatment of virus plus cells or virus alone with PS20 potently inhibited HIV-1 infection, with an IC 50 of 0.60 ± 0.1 mM and 22.41 ± 4.2 mM, respectively. Pretreatment of target cells alone had no anti-HIV-1 activity [Figure 1]d. Taken together, the above experiments provide strong evidences that PS20 inhibits HIV-1 infection likely by interacting with viral envelope glycoprotein but not with cellular receptors or co-receptors.
PS20 has Low Toxicity to Human Genital Cells and Vagina Lactobacilli
For preventing sexual transmission of HIV-1, microbicides should be mostly applied vaginally. Lactobacilli are the dominant member in vaginal flora, playing a key role in vaginal health, and often used for evaluating the safety of microbicide application. L. delbrueckii isolated from normal human vagina was used in the present study. The MIC of PS20 to the bacterium was >
1000 mM, the highest concentration in the culture medium [Table 3]. Human genital cells, including primary human foreskin fibroblast cells, cell lines ME-180 and HeLa were used for evaluating the safety profile of PS20. The CC 50 values of PS20 for these cells were more than 70 mM [Table 3]. These results together demonstrate that PS20 has low toxicity to these cells.
|Table 3: Toxicity of PS20 to various human cells and vaginal lactobacilli|
Click here to view
Carbohydrate-derived drugs (such as Tamiflu and zanamivir) have been approved and used in the prevention and treatment of human influenza; sodium hyaluronate, a type of polysaccharide is applied for therapy of osteoarthritis.  In the present study, a polysaccharide sulfate, C. otophyllum glucan sulfate (PS20) demonstrated anti-HIV activity against R5 and X4 viruses. Both the time-of-addition experiment and pretreatment experiment showed that PS20 blocked the entry of HIV-1 by binding to envelope glycoprotein. In addition, PS20 demonstrated a good anti-HSV activity. PS20 molecule carries a large amount of sulfate anionic ions and is structurally similar to microbicide candidate Pro2000 under phase 3 clinical trial. 
| » Discussion|| |
According to recommendations for nonclinical development of topical microbicides,  the cytotoxicity of PS20 to human genital cells and vaginal lactobacilli was evaluated. The CC 50 of PS20 in ME180, HeLa, and primary foreskin fibroblast cells is more than 70 mM, and the MIC of PS20 to vaginal lactobacilli is more than 1000 mM, these data suggest that PS20 is safe for epithelium cells and vaginal bacterial flora. In conclusion, PS20 has good in vitro anti-HIV and anti-HSV activities and low toxicity to human genital cells and vaginal lactobacilli. As indicated by Lard-Whiteford et al. and Microbicide Development Strategy Working Groups,  further investigation of PS20 on the rest of the preclinical assessment will be needed for developing a topical microbicide.
| » References|| |
|1.||Shattock RJ, Moore JP. Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol 2003;1:25-34. |
|2.||Vlietinck AJ, De Bruyne T, Apers S, Pieters LA. Plant-derived leading compounds for chemotherapy of human immunodeficiency virus (HIV) infection. Planta Med 1998;64:97-109. |
|3.||Matthee G, Wright AD, Konig GM. HIV reverse transcriptase inhibitors of natural origin. Planta Med 1999;65:493-506. |
|4.||Alliance for microbicide Development [Internet]. Microbicides watches 2006. Available from: http://www.microbicide.org/microbicideinfo/reference/MicrobicideWatch.April2006.FINAL.pdf. [Last accessed on 2010 Aug 2]. |
|5.||Mu QZ, ShenYM, Zhou QL. Beta-D-(1-4)-glucan sulfate. China patent CN1206717, 1999. |
|6.||Tao J, Mu Q, Ben K, Yang J, Liang Z, Cao X. A novel polysaccharide sulfate (PS20) is a potential microbicide candidate. A-017, Antwerp, Belgium: Conference Abstracts of Microbicides; 12-15 May 2002. |
|7.||Amit M, Shariki C, Margulets V, Itskovitz-Eldor J. Human feeder layers for human embryonic stem cells. Biol Reprod 2003;70:837-45. |
|8.||Tao J, Hu QX, Yang J, Li RR, Li XY, Lu CP, et al. In vitro anti-HIV and -HSV activity and safety of sodium rutin sulfate as a microbicide candidate. Antiviral Res 2007;75:227-33. |
|9.||Zheng YT, Ben KL. Anti-HIV-1 activity of trichobitacin, a novel ribosome inactivating protein. Acta Pharmacol Sin 2000;21:179-82. |
|10.||Walker BD, Kowalski M, Goh WC, Kozarsky K, Krieger M, Rosen C, et al. Inhibition of human immunodeficiency virus syncytium formation and virus replication by castanospermine. Proc Natl Acad Sci USA 1987;84:8120-4. |
|11.||Motakis D, Parniak MA. A tight-binding mode of inhibition is essential for anti-human immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002;46:1851-6. |
|12.||Talarico LB, Zibetti RG, Faria PC, Scolaro LA, Duarte ME, Noseda MD, et al. Anti-herpes simplex virus activity of sulfated galactans from the red seaweeds Gymnogongrus griffithsiae and Cryptonemia crenulatal. Int J Biol Macromol 2004;34:63-71. |
|13.||Schmidtke M, Schnittler U, Jahn B, Dahse H, Stelzner A. A rapid assay for evaluation of antiviral activity against coxsackie virus B3, influenza virus A, and herpes simplex virus type 1. J Virol Methods 2001;95:133-43. |
|14.||Zheng YT, Zhang WF, Ben KL, Wang JH. In vitro immunotoxicity and cytotoxicity of trichosanthin against human normal immunocytes and leukemia-lymphoma cells. Immunopharmacol Immunotoxicol 1995;17:69-79. |
|15.||Kang B, Li F, Yuan JL. Study of microbiology on a Lactobacillus dehrueckii DM8909. Chin J Microecol 2001;13:188-9. |
|16.||Ernst B, Magnani JL. From carbohydrate leads to glycomimetic drugs. Nat Rev Drug Discov 2009;8:661-77. |
|17.||Romer D, Brighty DW, Robson CL, Sattentau QJ. Candidate polyanionic microbicides inhibit human T-cell lymphotropic virus type 1 receptor interactions, cell-free infection, and cell-cell spread. Antimicrob Agents Chemother 2009;53:678-87. |
|18.||Lard-Whiteford SL, Matecka D, O'Rear JJ, Yuen IS, Litterst C, Reichelderfer P. International Working Group on Microbicides, Recommendations for the nonclinical development of topical microbicides for prevention of HIV transmission: An update. J Acquir Immune Defic Syndr 2004;36:541-52. |
|19.||Microbicide Development Strategy Working Groups. The Microbicide Development Strategy. Silver Spring, MD, USA: Alliance for Microbicide Development; August 2006. |
[Table 1], [Table 2], [Table 3]
|This article has been cited by|
||Aqueous Extracts of Thai Medicinal Plants Possess anti-HIV-1 Activity
| ||Sathit Panvilai, Chanita Napaswad, Jitra Limthongkul, Radeekorn Akkarawongsapat |
| ||Journal of Herbs, Spices & Medicinal Plants. 2021; 27(1): 1 |
|[Pubmed] | [DOI]|